Clinical Benefit Observed with Pembrolizumab in Heavily Pretreated Classical Hodgkin Lymphoma
Patients with classical Hodgkin lymphoma (cHL) who were heavily pretreated had clinical benefit from pembrolizumab (MK-3475).
Diagnosis & Disease Information
For Hodgkin Lymphoma, Perifosine Plus Sorafenib May Be Safe and Effective
Combination therapy with perifosine and sorafenib effective and safe for the treatment of relapsed or refractory Hodgkin lymphoma.
Updated Recommendations for Staging, Evaluation of Hodgkin and Non-Hodgkin Lymphoma
International group of hematologists released recommendations for evaluation and treatment response to Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).
For Patients with Hodgkin’s Lymphoma, Radiation Therapy Increases Survival
Patients with lymphoma who receive radiation therapy have an increased survival rate.
Hodgkin’s Lymphoma Survivors Face Higher Diabetes Risk
Para-aortic radiation with ≥36 Gy linked to increased risk of diabetes mellitus.
Patients With Hodgkin Lymphoma May Develop Third Malignancy
Hodgkin lymphoma survivors who have developed a second malignancy are at a higher risk of developing a third malignancy.
Proton Therapy May Be Safe for Hodgkin Lymphoma
Post-chemotherapy proton therapy has a similar success rate to more conventional methods.
MRI Catches Breast Cancer Early in Hodgkin Lymphoma Survivors
The largest clinical study to evaluate breast cancer screening of female survivors of childhood Hodgkin lymphoma, showed that MRI detected invasive breast tumors at very early stages, when cure rates are expected to be excellent.
Coronary Artery Disease Prevalent Among Hodgkin Lymphoma Survivors
New data show a high prevalence of coronary artery disease among survivors of Hodgkin lymphoma.
Post-Chemo PET Scan Results Indicative of Outcomes in Hodgkin Lymphoma
Patients with Hodgkin lymphoma who have PET-positive residual disease after chemotherapy and poor tumor shrinkage are at high risk of progression or relapse.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...